A “living drug” that could change the way we treat cancer

Carl June is the immunotherapy pioneer behind CAR T-cell therapy: a groundbreaking cancer treatment that supercharges part of a patient’s own immune system to attack and kill tumours.

He is the Director of the Centre for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at University of Pennsylvania’s Perelman School of Medicine .

In a talk about a breakthrough, he shares how three decades of research culminated in a therapy that’s eradicated cases of leukemia once thought to be incurable, and explains how it could be used to fight other types of cancer.

The American Society for Clinical Investigation has recognised Carl H. June, MD, as the recipient of its sixth annual Harrington Prize in Innovation. The prize recognises a physician-scientist who has advanced scientific innovation, creativity and possible clinical applications.

You may also like The Gut-Brain connection